Search
Perampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalPerampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersRegorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalRegorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBedaquiline
go.drugbank.com/drugs/DB08903ApprovedInvestigationalBedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial acti...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTrametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigationalTrametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InducersAfatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalAfatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for pat...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLevomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigationalLevomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. Levomilnacipran is the more active 1S,2R-enantiomer in the ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalTo date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administer...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsIcotinib
go.drugbank.com/drugs/DB11737InvestigationalIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersCabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigationalCabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine. Early research into cabotegravir showed it had lower oral bioavailability than dolutegr...
Categories: P-glycoprotein substrates